AGENDA

		DAY 1	
TIMING	DURATION (min)	TITLE	SPEAKER
9:00-9:50	50	Regi	stration and coffee
9:50-10:00	10	Welcome and opening remarks	Péter Krajcsi, PhD, Chief Scientific Officer, SOLVO Biotechnology, Hungary
10:00-10:40	40	Keynote: Ki determination in vitro and its impact on modelling and prediction of DDI	Yuichi Sugiyama, PhD, Head of Sugiyama Laboratory, RIKEN, Japan
		Session 1: Drug disposition and drug-drug interaction,	Chair: Péter Krajcsi, PhD, Chief Scientific Officer, SOLVO Biotechnology
10:4011:10	30	Drug disposition classification systems - a comparative review of BDDCS, ECCS and ECCCS	Birk Poller, PhD, Lab Head, PK Sciences Department, Novartis, Switzerland
11:10-11:40	30	Assessment of unbound target site-concentration in brain and lungs: methodological considerations and practical implications	Irena Loryan, M.D., Ph.D., Researcher, Translational PKPD, Dept. Pharmaceutical Biosciences, Uppsala University
11:40-11:55	15	Poster presentation: Answering to the new FDA DDI guidance: Increasing the impact of IC50 studies through customization and modeling	Zhizhou Fang, PhD, Laboratory Head Drug Transporter, Senior Scientist II, DMP, Abbvie Ludwigshafen, Germany
11:55-13:00	65		Lunch Break
13:00-13:40	40	Keynote presentation: Endogenous transporter substrates as clinical biomarkers	Dietmar Weitz, PhD, Principal Scientist, Drug Metabolism and Pharmacokinetics FF, Sanofi-Aventis Deutschland GmbH R&D, Germany
		Session 2: Biomarkers, Chair: Krisztina Herédi-Szabo	6,PhD, Principal Scientist, ADME-Tox Services, SOLVO Biotechnology
13:40-14:10	30	Mass spectrometry-based quantification of transporter proteins and metabolizing enzymes: an update on advantages and challenges	Stefan Oswald, PhD, Assistant Professor at the Department of Clinical Pharmacology, University Medici Greifswald, Germany
14:10-14:40	30	A transporter, a nuclease and a metabolite: the trio orchestrating connective tissue calcification	András Váradi, PhD ,Institute of Enzymology, RCNS, Hungarian Academy of Sciences, Budapest, Hungar
14:40-14:55	15	Poster presentation: Determination of reference values of MDR-ABC transporter activities in CD3+ T lymphocytes by using SOLVO MDQ Kit™	Katalin Filkor, PhD, Lead Scientist, MDQuest, Szeged, Hungary
14:55-15:25	30	Keynote presentation: Epacadostat: Transport and Metabolism of A First in Class IDO1	Coffee Break
15:25-16:05	40	Inhibitor for Immuno-Oncology	Yan Zhang, Ph.D, Associate Director, Incyte Corporation, Drug Metabolism Pharmacokinetics & Clinical Pharmacology, US
		Session 3: Disease and therapy, Chair: F	toelof de Wilde, Director of Sales, SOLVO Biotechnology
16:05-16:35	30	Transporters in antimalarial drug action and resistance	Sanjeev Krishna, MA, MBChB, FRCP, DPhil, ScD, FMedSci, Professor of Molecular Parasitology and Medicine, St. George's, University of London, UK
16:35-16:50	15	Poster presentation: Optimization of an in vitro assay for identification of NTCP inhibitors	Pieter Van Brantegem, Drug Delivery and Disposition, KU Leuven Department of Pharmaceutical and Sciences, Leuven, Belgium Pharmacological
16:50-17:05	15	Small Currents – Big Potential. Electrophysiology for transporters using the "SURFE2R" technology	Maria Barthmes, PhD, Application Scientist & Product Manager, SURFE2R Family, Nanion Technologies GmbH, Germany
17:05-19:00			POSTER SESSION
	115		
19:00-22:00	180		DINNER
19:00-22:00		DAY 2	DINNER
19:00-22:00 TIMING	180	DAY 2	DINNER SPEAKER
	180	TITLE Keynote presentation: Studying disposition of uremic waste products: can we develop	SPEAKER Roos Masereeuw, PhD, Professor and Head of the Experimental pharmacology group at Utrecht Institu
TIMING	180 DURATION (min)	TITLE Keynote presentation: Studying disposition of uremic waste products: can we develop novel therapeutic strategies to treat chronic kidney disease?	SPEAKER Roos Masereeuw, PhD, Professor and Head of the Experimental pharmacology group at Utrecht Institution for Pharmaceutical Sciences, The Netherlands
TIMING	180 DURATION (min)	TITLE Keynote presentation: Studying disposition of uremic waste products: can we develop novel therapeutic strategies to treat chronic kidney disease?	SPEAKER Roos Masereeuw, PhD, Professor and Head of the Experimental pharmacology group at Utrecht Institu
TIMING	180 DURATION (min)	TITLE Keynote presentation: Studying disposition of uremic waste products: can we develop novel therapeutic strategies to treat chronic kidney disease?	SPEAKER Roos Masereeuw, PhD, Professor and Head of the Experimental pharmacology group at Utrecht Institution for Pharmaceutical Sciences, The Netherlands
TIMING 8:20-9:00 9:00-9:30	DURATION (min)	TITLE Keynote presentation: Studying disposition of uremic waste products: can we develop novel therapeutic strategies to treat chronic kidney disease? Session 4: Organ impairment/toxicity, Chair: Zsu	SPEAKER Roos Masereeuw, PhD, Professor and Head of the Experimental pharmacology group at Utrecht Institution for Pharmaceutical Sciences, The Netherlands zsanna Gaborik, PhD, Head of Laboratory, SOLVO Biotechnology
TIMING 8:20-9:00 9:00-9:30 9:30-10:00	DURATION (min) 40	TITLE Keynote presentation: Studying disposition of uremic waste products: can we develop novel therapeutic strategies to treat chronic kidney disease? Session 4: Organ impairment/toxicity, Chair: Zsu Hepatotoxicity testing - primary hepatocyte and hepatic cell line models Hepatic bile salt transport	SPEAKER Roos Masereeuw, PhD, Professor and Head of the Experimental pharmacology group at Utrecht Institutor Pharmaceutical Sciences, The Netherlands zsanna Gaborik, PhD, Head of Laboratory, SOLVO Biotechnology Lysiane Richert, PhD, Professor in Cell Biology and Toxicology, Scientific Director, KaLy-Cell, France Péter Krajcsi, PhD, Chief Scientific Officer, SOLVO Biotechnology, Hungary Coffee Break
TIMING 8:20-9:00 9:00-9:30 9:30-10:00	180 DURATION (min) 40 30 30	TITLE Keynote presentation: Studying disposition of uremic waste products: can we develop novel therapeutic strategies to treat chronic kidney disease? Session 4: Organ impairment/toxicity, Chair: Zsu Hepatotoxicity testing - primary hepatocyte and hepatic cell line models	SPEAKER Roos Masereeuw, PhD, Professor and Head of the Experimental pharmacology group at Utrecht Institutor Pharmaceutical Sciences, The Netherlands zsanna Gaborik, PhD, Head of Laboratory, SOLVO Biotechnology Lysiane Richert, PhD, Professor in Cell Biology and Toxicology, Scientific Director, KaLy-Cell, France Péter Krajcsi, PhD, Chief Scientific Officer, SOLVO Biotechnology, Hungary Coffee Break
TIMING 8:20-9:00 9:00-9:30 9:30-10:00	180 DURATION (min) 40 30 30 30	Keynote presentation: Studying disposition of uremic waste products: can we develop novel therapeutic strategies to treat chronic kidney disease? Session 4: Organ impairment/toxicity, Chair: Zst Hepatotoxicity testing - primary hepatocyte and hepatic cell line models Hepatic bile salt transport Keynote presentation: Effect of cigarette smoke extract on the function and expression of membrane transporters in alveolar epithelial cells	SPEAKER Roos Masereeuw, PhD, Professor and Head of the Experimental pharmacology group at Utrecht Institt for Pharmaceutical Sciences, The Netherlands zsanna Gaborik, PhD, Head of Laboratory, SOLVO Biotechnology Lysiane Richert, PhD, Professor in Cell Biology and Toxicology, Scientific Director, KaLy-Cell, France Péter Krajcsi, PhD, Chief Scientific Officer, SOLVO Biotechnology, Hungary Coffee Break Mikihisa Takano, PhD, Professor, Graduate School of Biomedical & Health Sciences, Hiroshima University
TIMING 8:20-9:00 9:00-9:30 9:30-10:00 10:00-10:30	180 DURATION (min) 40 30 30 30	Keynote presentation: Studying disposition of uremic waste products: can we develop novel therapeutic strategies to treat chronic kidney disease? Session 4: Organ impairment/toxicity, Chair: Zst Hepatotoxicity testing - primary hepatocyte and hepatic cell line models Hepatic bile salt transport Keynote presentation: Effect of cigarette smoke extract on the function and expression of membrane transporters in alveolar epithelial cells	SPEAKER Roos Masereeuw, PhD, Professor and Head of the Experimental pharmacology group at Utrecht Institution of Pharmaceutical Sciences, The Netherlands zsanna Gaborik, PhD, Head of Laboratory, SOLVO Biotechnology Lysiane Richert, PhD, Professor in Cell Biology and Toxicology, Scientific Director, KaLy-Cell, France Péter Krajcsi, PhD, Chief Scientific Officer, SOLVO Biotechnology, Hungary Coffee Break Mikihisa Takano, PhD, Professor, Graduate School of Biomedical & Health Sciences, Hiroshima University Japan se Kis, PhD, Director of R&D and Production, SOLVO Biotechnology Emmanuelle Reboul, PhD, , Researcher at the French National Institute of Agronomical Research (INRA) Research axis of the Micronutrition Team "Bioavailability of fat-soluble micronutrients", Center for
TIMING 8:20-9:00 9:00-9:30 9:30-10:00 10:00-10:30 11:10-11:40	180 DURATION (min) 40 30 30 40	Keynote presentation: Studying disposition of uremic waste products: can we develop novel therapeutic strategies to treat chronic kidney disease? Session 4: Organ impairment/toxicity, Chair: Zsu Hepatotoxicity testing - primary hepatocyte and hepatic cell line models Hepatic bile salt transport Keynote presentation: Effect of cigarette smoke extract on the function and expression of membrane transporters in alveolar epithelial cells Session 5: Xenobiotics and endobiotics, Chair: Eme	SPEAKER Roos Masereeuw, PhD, Professor and Head of the Experimental pharmacology group at Utrecht Institution of Pharmaceutical Sciences, The Netherlands zsanna Gaborik, PhD, Head of Laboratory, SOLVO Biotechnology Lysiane Richert, PhD, Professor in Cell Biology and Toxicology, Scientific Director, KaLy-Cell, France Péter Krajcsi, PhD, Chief Scientific Officer, SOLVO Biotechnology, Hungary Coffee Break Mikihisa Takano, PhD, Professor, Graduate School of Biomedical & Health Sciences, Hiroshima University Japan se Kis, PhD, Director of R&D and Production, SOLVO Biotechnology Emmanuelle Reboul, PhD, , Researcher at the French National Institute of Agronomical Research (INRA)
8:20-9:00	30 30 30 30 30	TITLE Keynote presentation: Studying disposition of uremic waste products: can we develop novel therapeutic strategies to treat chronic kidney disease? Session 4: Organ impairment/toxicity, Chair: Zsu Hepatotoxicity testing - primary hepatocyte and hepatic cell line models Hepatic bile salt transport Keynote presentation: Effect of cigarette smoke extract on the function and expression of membrane transporters in alveolar epithelial cells Session 5: Xenobiotics and endobiotics, Chair: Eme	SPEAKER Roos Masereeuw, PhD, Professor and Head of the Experimental pharmacology group at Utrecht Institution Pharmaceutical Sciences, The Netherlands zsanna Gaborik, PhD, Head of Laboratory, SOLVO Biotechnology Lysiane Richert, PhD, Professor in Cell Biology and Toxicology, Scientific Director, KaLy-Cell, France Péter Krajcsi, PhD, Chief Scientific Officer, SOLVO Biotechnology, Hungary Coffee Break Mikihisa Takano, PhD, Professor, Graduate School of Biomedical & Health Sciences, Hiroshima University Japan se Kis, PhD, Director of R&D and Production, SOLVO Biotechnology Emmanuelle Reboul, PhD, , Researcher at the French National Institute of Agronomical Research (INRA Research axis of the Micronutrition Team "Bioavailability of fat-soluble micronutrients", Center for Cardiovascular and Nutrition Research, Aix-Marseille University, France
TIMING 8:20-9:00 9:00-9:30 9:30-10:00 10:00-10:30 11:10-11:40 11:40-12:10	30 30 30 30 30 30	Keynote presentation: Studying disposition of uremic waste products: can we develop novel therapeutic strategies to treat chronic kidney disease? Session 4: Organ impairment/toxicity, Chair: Zsu Hepatotoxicity testing - primary hepatocyte and hepatic cell line models Hepatic bile salt transport Keynote presentation: Effect of cigarette smoke extract on the function and expression of membrane transporters in alveolar epithelial cells Session 5: Xenobiotics and endobiotics, Chair: Emerican transport of fat-soluble vitamins Thyroid hormone transport Poster presentation: The role of human MRP2 in cellular efflux of microcystins, a type of	SPEAKER Roos Masereeuw, PhD, Professor and Head of the Experimental pharmacology group at Utrecht Institutor Pharmaceutical Sciences, The Netherlands zsanna Gaborik, PhD, Head of Laboratory, SOLVO Biotechnology Lysiane Richert, PhD, Professor in Cell Biology and Toxicology, Scientific Director, KaLy-Cell, France Péter Krajcsi, PhD, Chief Scientific Officer, SOLVO Biotechnology, Hungary Coffee Break Mikihisa Takano, PhD, Professor, Graduate School of Biomedical & Health Sciences, Hiroshima Univers Japan se Kis, PhD, Director of R&D and Production, SOLVO Biotechnology Emmanuelle Reboul, PhD, , Researcher at the French National Institute of Agronomical Research (INRA Research axis of the Micronutrition Team "Bioavailability of fat-soluble micronutrients", Center for Cardiovascular and Nutrition Research, Aix-Marseille University, France Theo Visser, PhD, Professor at Erasmus University Medical Center, Rotterdam, The Netherlands